Evaluation of lung protection of Sanghuangporus sanghuang through TLR4/NF-κB/MAPK, keap1/Nrf2/HO-1, CaMKK/AMPK/Sirt1, and TGF-β/SMAD3 signaling pathways mediating apoptosis and autophagy

doi:10.1016/j.biopha.2023.115080

CNU IR > Offices > 456 > Item 310902800/34854

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34854

Title:	Evaluation of lung protection of Sanghuangporus sanghuang through TLR4/NF-κB/MAPK, keap1/Nrf2/HO-1, CaMKK/AMPK/Sirt1, and TGF-β/SMAD3 signaling pathways mediating apoptosis and autophagy
Authors:	Chien, Liang-Hsuan Deng, Jeng-Shyan Jiang, Wen-Ping Chou, Ya-Ni Lin, Jaung-Geng Huang, Guan-Jhong
Contributors:	China Med Univ, Coll Chinese Med, Dept Chinese Pharmaceut Sci & Chinese Med Resource Tajen Univ, Coll Pharm & Hlth Care, Dept Pharm Asia Univ, Dept Food Nutr & Hlth Biotechnol Chia Nan Univ Pharm & Sci, Dept Pharm China Med Univ, Dept Chinese Med China Med Univ, Coll Chinese Med, Sch Chinese Med China Med Univ, Coll Chinese Med, Dept Chinese Pharmaceut Sci & Chinese Med Resource
Keywords:	Sanghuangporus sanghuang Idiopathic pulmonary fibrosis Anti-inflammation Oxidative stress Apoptosis Autophagy
Date:	2023
Issue Date:	2024-12-25 11:04:36 (UTC+8)
Publisher:	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Abstract:	Idiopathic pulmonary fibrosis (IPF) is a type of interstitial pneumonia characterized by chronic and progressive fibrosis with an unknown etiology. Previous pharmacological studies have shown that Sanghuangporus sanghuang possesses various beneficial properties including immunomodulatory, hepatoprotective, antitumor, antidiabetic, anti-inflammatory, and neuroprotective effects. This study used a bleomycin (BLM)-induced IPF mouse model to illustrate the possible benefits of SS in ameliorating IPF. BLM was administered on day 1 to establish a pulmonary fibrosis mouse model, and SS was administered through oral gavage for 21 d. Hematoxylin and eosin (H & E) and Masson's trichrome staining results showed that SS significantly reduced tissue damage and decreased fibrosis expression. We observed that SS treatment resulted in a substantial lowering in the level of pro-inflammatory cytokines like TGF-& beta;, TNF-& alpha;, IL-1 & beta;, and IL-6 as well as MPO. In addition, we observed a notable increase in glutathione (GSH) levels. Western blot analysis of SS showed that it reduces inflammatory factors (TWEAK, iNOS, and COX-2), MAPK (JNK, p-ERK, and p-38), fibrosis-related molecules (TGF-& beta;, SMAD3, fibronectin, collagen, & alpha;-SMA, MMP2, and MMP9), apoptosis (p53, p21, and Bax), and autophagy (Beclin-1, LC3A/B-I/II, and p62), and notably increases caspase 3, Bcl-2, and antioxidant (Catalase, GPx3, and SOD-1) levels. SS alleviates IPF by regulating the TLR4/NF-& kappa;B/MAPK, Keap1/Nrf2/HO-1, CaMKK/AMPK/Sirt1, and TGF-& beta;/SMAD3 pathways. These results suggest that SS has a pharmacological activity that protects the lungs and has the potential to improve pulmonary fibrosis.
Relation:	Biomedicine & Pharmacotherapy, v.165, Article 115080
Appears in Collections:	[Offices] 456

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	5	View/Open

Loading...